HROW · Nasdaq · CIK 0001360214
HARROW, INC.
HARROW, INC.’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G/A filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $272.3M and net income of -$5.1M, according to its XBRL data on EDGAR. Its EDGAR record lists 15 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- HARROW, INC.
- Ticker
- HROW
- SEC Central Index Key (CIK)
- 0001360214
- Industry (SIC)
- Pharmaceutical Preparations (code 2834)
- Business address
- NASHVILLE, TN
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #2398 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from HARROW, INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $72.5M | $88.6M | $130.2M | $199.6M | $272.3M |
| Net income | -$18.0M | -$14.1M | -$24.4M | -$17.5M | -$5.1M |
| Diluted EPS | -$0.69 | -$0.51 | -$0.75 | -$0.49 | -$0.14 |
| Total assets | $98.3M | $157.4M | $312.2M | $389.0M | $399.5M |
| Cash and equivalents | $42.2M | $96.3M | $74.1M | $47.2M | $72.9M |
XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareBasicAndDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Mar 2, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 10, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Oct 5, 2026 | 8-K | Material agreement; Acquisition or disposition completed; Regulation FD disclosure· period Oct 1, 2026 | Document · Index |
| Apr 24, 2026 | DEF 14A | Definitive proxy statement· period Dec 31, 2025 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about HARROW, INC., by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 27, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Oct 5, 2026 | 8-K | Material agreement; Acquisition or disposition completed; Regulation FD disclosure· period Oct 1, 2026 | Document · Index |
| Sep 4, 2026 | 8-K | Director or officer change· period Sep 4, 2026 | Document · Index |
| Aug 21, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 14, 2026 | Document · Index |
| Aug 10, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 10, 2026 | 8-K | Results of operations; Regulation FD disclosure· period Aug 10, 2026 | Document · Index |
| Aug 6, 2026 | 8-K | Material agreement; Regulation FD disclosure· period Aug 3, 2026 | Document · Index |
| Jul 31, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Jun 22, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026 | Document · Index |
| Jun 22, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026 | Document · Index |
| Jun 22, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026 | Document · Index |
| Jun 22, 2026 | 8-K | Shareholder vote results· period Jun 18, 2026 | Document · Index |
| Jun 3, 2026 | 8-K | Regulation FD disclosure· period Jun 3, 2026 | Document · Index |
| May 19, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 18, 2026 | Document · Index |
| May 19, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 18, 2026 | Document · Index |
| May 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 15, 2026 | Document · Index |
| May 15, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 14, 2026 | Document · Index |
| May 15, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 14, 2026 | Document · Index |
| May 11, 2026 | 10-Q | Quarterly report· period Mar 31, 2026 | Document · Index |
| May 11, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| May 11, 2026 | 8-K | Results of operations; Regulation FD disclosure· period May 11, 2026 | Document · Index |
| Apr 24, 2026 | DEFA14A | Additional proxy soliciting materials | Document · Index |
| Apr 24, 2026 | DEF 14A | Definitive proxy statement· period Dec 31, 2025 | Document · Index |
| Mar 27, 2026 | 8-K | Material agreement; New financial obligation; Other events· period Mar 24, 2026 | Document · Index |
| Mar 27, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Mar 24, 2026 | 8-K | Other events· period Mar 24, 2026 | Document · Index |
| Mar 24, 2026 | 8-K | Other events· period Mar 24, 2026 | Document · Index |
| Mar 11, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Mar 10, 2026 | 8-K | Regulation FD disclosure· period Mar 10, 2026 | Document · Index |
| Mar 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 3, 2026 | Document · Index |
| Mar 3, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Feb 27, 2026 | Document · Index |
| Mar 2, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Mar 2, 2026 | 8-K | Results of operations; Regulation FD disclosure· period Mar 2, 2026 | Document · Index |
| Feb 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jan 30, 2026 | Document · Index |
| Feb 2, 2026 | 3 | Initial statement of beneficial ownership· period Jan 30, 2026 | Document · Index |
| Feb 2, 2026 | 8-K | Results of operations; Director or officer change· period Jan 30, 2026 | Document · Index |
| Jan 8, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jan 6, 2026 | Document · Index |
| Dec 16, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 12, 2025 | Document · Index |
| Dec 16, 2025 | 4 | Statement of changes in beneficial ownership (insider trade)· period Dec 12, 2025 | Document · Index |
Insider filing activity
15 Form 4 filings appear in HARROW, INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Pharmaceutical Preparations
- LLY ELI LILLY & Co
- JNJ JOHNSON & JOHNSON
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- NVS NOVARTIS AG
- AZN ASTRAZENECA PLC
- ABT ABBOTT LABORATORIES
- NVO NOVO NORDISK A S
All 194 companies in Pharmaceutical Preparations· Companies headquartered in Tennessee
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001360214 and XBRL company facts. HARROW, INC. on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement